



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 9/00, 9/20	A1	(11) International Publication Number: WO 93/12765 (43) International Publication Date: 8 July 1993 (08.07.93)
(21) International Application Number: PCT/US92/11014 (22) International Filing Date: 18 December 1992 (18.12.92) (30) Priority data: 815,304 27 December 1991 (27.12.91) US 902,188 29 July 1992 (29.07.92) US (71) Applicant: MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). (72) Inventors: RORK, Gerald, S. ; Rural Route 5, Box 274-B, Lawrence, KS 66046 (US). PIPKIN, James, D. ; 3613 Riverview Road, Lawrence, KS 66049 (US). (74) Agent: BIGLEY, Frank, P.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		(81) Designated States: BG, CS, FI, HU, KR, NO, PL, RO, RU. Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: A CONTROLLED RELEASE DRUG DISPERSION DELIVERY DEVICE (57) Abstract A device for the controlled delivery of a beneficial agent as a gelatinous dispersion consisting of (i) a core which contains a beneficial agent, a polymer which forms gelatinous microscopic particles upon hydration and if desired an agent to modulate the hydration of the polymer; and (ii) an impermeable, insoluble coating which adheres to and surrounds the core and contains apertures which provide an area for the hydration and release of a dispersion comprising gelatinous microscopic particles.		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

5

TITLE OF THE INVENTION

10 A CONTROLLED RELEASE DRUG Dispersion DELIVERY DEVICE

FIELD OF THE INVENTION

15 This invention pertains to both a useful and novel drug-delivery device for dispensing a drug to an environment of use. Particularly, the invention pertains to a system that releases a drug in a controlled fashion, by creating gelatinous microscopic particles of polymer and in so doing, 20 generates a dispersion of drug among the microscopic particles. The dispersion then moves from the device surface into the aqueous environment of use.

25 The device is composed of a core containing a beneficial agent such as a medicament, a polymer which provides gelatinous microscopic particles upon hydration and if desired a hydration modulating agent. The device is 30 completely coated with an insoluble, impermeable coating.

The coating contains apertures to expose discrete portions of the surface of the core. The delivery rate of the medicament is a function of the core composition as well as the number and size of the apertures.

5 In the environment of use, biological fluid contacts the exposed portions of the core surface where hydration of the polymer at the surface begins. As the particles of polymer at the exposed surface absorb water, a gelatinous
10 microscopic dispersion of particles results. Mixed with and dispersed in these microscopic particles are the other components of the core formulation, such as a medicament.

15 The exposed portion of the core surface is bounded on all sides by the coating. Hydration of the polymer occurs at the exposed surface of the core, resulting in the steady-state formation of a gelatinous microscopic particle
20 dispersion within which the drug is dispensed and which moves into the environment of use.

 The rate of release of the beneficial agent is not dependent upon the solubility of the beneficial agent in the
25 biological fluid. Rather, the release rate is essentially dependent upon the rate at which the gelatinous microscopic particle dispersion forms at the exposed surface of the device core and exudes from the device carrying with it the

beneficial agent and any other core excipient materials that are present.

BACKGROUND OF THE INVENTION

The need for systems that can deliver any drug at a controlled rate of release to an environment of use over a specified period of time is well established.

U.S. Patent 4,814,182 discloses the use of rods or slabs of pre-hydrated and swelled polyethylene oxide hydrogel. The polymer is impregnated with a biologically active agent during the hydration procedure. The hydrated polymer is then dried and partially coated with an impermeable, insoluble material. When placed in an aqueous environment, the polymer swells but does not dissolve or disintegrate. The entrapped active ingredient is released from the polymer by diffusion. The mechanism of release is based on the ability of the soluble drug to diffuse through the rehydrated hydrogel and move into the aqueous environment.

U.S. Patent 4,839,177 discloses the use of hydrogels compressed to defined geometric forms. In this device, the polymer is mixed with biologically active ingredients to form a core which is affixed to a "support platform" made of an insoluble polymeric material. When hydrated, the

swellable, gellable hydrogel expands beyond the device and establishes a superstructure from which the active agent is released either by diffusion, if the active agent is soluble, or by erosion, if the active agent is insoluble.

5 The generation and maintenance of the superstructure is vital to the proper operation of this device.

An osmotic dosage form which utilizes a semipermeable wall containing at least one "exit means" which passes
10 through the wall, surrounding a core containing an osmotic agent, a neutral and ionizable hydrogel and an active ingredient is taught in U.S. patent 4,971,790. The coating of this device is permeable to water from the environment of
15 use. Water moves into the core through the semipermeable membrane. Once inside the device, the water solubilizes the osmotic agent, and hydrates the hydrogels. Pressure builds up inside the device. Ultimately, the solubilized hydrogel,
20 containing the beneficial agent, and other core excipients are pumped out of the core, under pressure, through an exit means and into the environment of use.

25 The existing technology is limited since diffusion controlled systems are effective only when soluble active agents are dispensed. For osmotically controlled devices, the technology relies upon a wall permeable to the passage

30

of fluid present in the environment of use. Furthermore, these devices require a wall of carefully controlled permeability.

Devices which rely upon the establishment of an extra device superstructure can be altered during in vivo transit, for example, in the gastrointestinal tract. If portions of the superstructure break away, greater surface area is exposed to the environment and unpredictable release of the active agent may result.

The usefulness of the above devices would be increased if a device and method were provided to improve the delivery of drugs independent of their solubility so that diffusion from a swelled polymer or through the superstructure of a polymeric matrix could be avoided. Further utility would result from a methodology which provides a device where the generation of an extra tablet structure could be avoided and the dry ingredients could be contained within a protective coating until released from the device. This would prevent the chance of premature erosion and uncontrolled release of the active agent as well as provide enhanced stability for those active agents that are labile in the fluid of the environment of use.

DESCRIPTION OF DRAWINGS

Fig. 1 is a schematic representation of one embodiment of the instant invention. The device 10, has a core composition 11, comprised of a beneficial agent 12 and polymer 13 capable of forming a gelatinous microscopic particle dispersion upon hydration. The core may optionally
5 contain a polymer hydration modulating agent 14 and other tablet forming excipients 15. The core is surrounded by an insoluble, impermeable coating 16, with a plurality of
10 apertures 17 which expose the core surface to the environment of use.

In operation, aqueous solution, from the environment of use, contacts the surface of the core that is exposed within
15 the apertures 17. The available water begins to hydrate the polymer (13) and gelatinous microscopic particles form at the surface of the core. If present, the polymer hydration modulating agent 14, at the exposed core surface, is
20 solubilized and establishes the environment required for controlled of polymer hydration.

As the polymer particles 13 are hydrated, the gelatinous microscopic particles move from the surface. At
25 the same time, the gelatinous microscopic particles move the beneficial agent 12 from the surrounding surface into the environment as well. These particles of beneficial agent
30

move from the core surface into the environment of use in a dispersion with the gelatinous microscopic particles. As a result, controlling the surface area of the core which is exposed to the environment of use, effectively controls the delivery rate of medicament to the environment.

5

The instant invention provides a novel device for delivery of an active or beneficial agent (drug), in a dispersion, and produces a beneficial effect which overcomes the disadvantages associated with prior art devices.

10

The instant invention also provides a device for delivering an active or beneficial agent, in situ as a dispersion, at a controlled rate over a specified period of time, which delivery is controlled by selection of components of the device and not the environment surrounding the device.

15

Further, the instant invention provides a device for controlled delivery of an beneficial agent where the release rate of the beneficial agent is neither related to the solubility of the beneficial agent nor to the in vivo establishment of an extra tablet superstructure.

20

25

Additionally, the instant invention provides a device for controlled delivery of an beneficial agent where delivery occurs from the surface of the device not from

30

within a core so that delivery rate is not dependent on diffusion of the active ingredient from inside the device to the environment of use.

Other features and advantages of the invention will be apparent to those skilled in the art from the following detailed description of the invention, taken in conjunction with the drawings and accompanying claims.

DETAILED DESCRIPTION OF THE INVENTION

The novel device of this invention consists essentially of a drug delivery device for the controlled in situ production and release of a dispersion containing a beneficial agent, consisting essentially of:

(A) a compressed core prepared from an admixture comprising (i) a therapeutically effective amount of a beneficial agent; and

(ii) a polymer which upon hydration forms gelatinous microscopic particles;

(B) a water insoluble, water impermeable polymeric coating, which surrounds and adheres to the core, the coating having a plurality of apertures exposing between about 1 and about 75% of the core surface.

By "drug delivery device" is meant, a dosage form that provides a convenient means of delivering a drug to a

subject. The subject can be a human or any other animal. The device is designed to be useful for the delivery of a drug by any pharmaceutically accepted means such as by swallowing, retaining it within the mouth until the beneficial agent has been dispensed, placing it within the buccal cavity, or the like.

By "controlled" production is meant that the rate of release of the beneficial agent, that is the amount of beneficial agent released from the device to the environment of use, follows a predetermined pattern. Thus, relatively constant or predictably varying amounts of the beneficial agent can be dispensed over a specified period of time.

The "gelatinous microscopic particles" are composed of discrete particles of hydrated polymer. Both size and hydration rate of these gelatinous microscopic particles are characteristics of the individual polymers. Illustrative of this type of polymer are sodium polyacrylate, particularly those compositions sold under the trade names "AQUAKEEP® J-550", "AQUAKEEP® J-400", which are trade names for sodium acrylate polymer produced by Seitetsu Kagaku Co., Ltd., Hyogo, Japan. The "AQUAKEEP®" polymers are generically described in United States Patent 4,340,706. Also illustrative of this type of polymer are

carboxypolymethylenes prepared from acrylic acid cross-linked with allyl ethers of sucrose or pentaerythritol and sold under the trade names "CARBOPOL® 934P" and "CARBOPOL® 974P", which are trade names for two carbomer type polymers produced by B.F. Goodrich Chemical Company, Cleveland, Ohio.

5 These latter polymers are generically described in United States Patent 2,909,462 and in the National Formulary XVII at p 1911, CAS Registry Number 9003-01-4. All of the

10 forgoing references are hereby incorporated by reference.

In the dry state, CARBOPOL® 974P and CARBOPOL® 934P particles range in size from about 2 to about 7 microns. When these particles are hydrated, gelatinous microscopic

15 particles of about 20 microns are produced. When AQUAKEEP® J-550 or AQUAKEEP® J-400 particles are hydrated, the diameter of the gelatinous microscopic particles can range

in size from 100 to 1000 microns.

20 Once the drug delivery device is within the environment of use, the polymer of the compressed core which is exposed to the ambient aqueous solution at the coating apertures, begins to hydrate and produce gelatinous microscopic

25 particles. By "in situ production and release of a dispersion" is meant that during the production of the gelatinous microscopic particles, soluble and insoluble core

components located near the polymer particles become dispersed and mixed in such a manner that a gelatinous dispersion is produced. The dispersion moves from the device into the aqueous solvent, bringing the beneficial agent into the environment of use. In this novel device,
5 the components of the compressed core move into the environment of use, carried along by the gelatinous microscopic particles, continually exposing new surfaces for further hydration and production of the dispersion.
10

By "gelatinous" is meant a semisolid system consisting of hydrated polymer interpenetrated by the aqueous solvent of the environment of use.

15 By "compressed core" is meant that an admixture of ingredients comprising a beneficial agent, a polymer which produces gelatinous microscopic particles when hydrated, and other ingredients that may affect any of (1) the rate of
20 production of the dispersion; (2) the stability of the components of the dosage form; or (3) the mixing or compression characteristics of the admixture, is blended in such a way to produce a uniform material. This uniform
25 material is then compressed, within a die, to produce a desired form, normally in the shape of a tablet, capsule or bolus.

The compressed core contains a therapeutically effective amount of beneficial agent and a polymer which upon hydration results in gelatinous microscopic particles. The term "beneficial agent" broadly includes any drug or mixture thereof, that can be delivered from the system to produce a beneficial result. The drug can be soluble in the fluid that makes contact with the exposed surface of the core or it can be essentially insoluble in the fluid.

In the specification and the accompanying claims, the term "drug" and its equivalents includes any physiologically or pharmacologically active substance that produces a localized or systemic effect or effects in animals. The term "animal" includes mammals, humans and primates such as domestic, household, sport or farm animals such as sheep, goats, cattle, horses and pigs, laboratory animals such as mice, rats and guinea pigs, fishes, avians, reptiles and zoo animals.

The active drug that can be delivered by the novel device of this invention, includes inorganic and organic compounds without limitation, including drugs that act on the peripheral nerves, adrenergic receptors, cholinergic receptors, nervous system, skeletal muscles, cardiovascular system, smooth muscles, blood circulatory system, synaptic

sites, neuroeffector junctional sites, endocrine and hormone systems, immunological system, reproductive system, skeletal systems, autocoid systems, alimentary and excretory systems, inhibitory and histamine systems, and those materials that act on the central nervous system such as hypnotics and sedatives.

Examples of beneficial drugs are disclosed in Remington's Pharmaceutical Sciences, 16th Ed., 1980,

published by Mack Publishing Co., Eaton, Pa.; and in The Pharmacological Basis of Therapeutics, by Goodman and Gilman, 6th Ed., 1980, published by the MacMillan Company, London; and in The Merck Index, 11th Edition, 1989,

published by Merck & Co., Rahway, N.J. The dissolved drug can be in various forms, such as charged molecules, charged molecular complexes or ionizable salts. Acceptable salts include, but are not limited to hydrochlorides, hydrobromide, sulfate, laurylate, palmitate, phosphate, nitrate, borate, acetate, maleate, malate, succinate, tromethamine, tartrate, oleate, salicylate, salts of metals, and amines or organic cations, for example quaternary ammonium.

Derivatives of drugs such as esters, ethers and amides without regard to their ionization and solubility

characteristics can be used alone or mixed with other drugs. Also, a drug can be used in a form that upon release from the device, is converted by enzymes, hydrolyzed by body pH or other metabolic processes to the original form, or to a biologically active form.

Specific examples of drugs that may be adapted for use include, Angiotensin-converting enzyme (ACE) inhibitors such as enalapril, lisinapril, and captopril; barbiturates such as pentobarbital sodium, phenobarbital, secobarbital, thiopental and mixtures thereof; heterocyclic hypnotics such as dioxopiperidines and glutarimides; hypnotics and sedatives such as amides and ureas, exemplified by diethylisovaleramide and α -bromoisovaleryl urea; hypnotic and sedative urethanes and disulfanes; psychic energizers such as isocarboxazid, nialamide, imipramine, amitriptyline hydrochloride, pargylene, and protryptiline hydrochloride; tranquilizers such as chlorpromazine, promazine, fluphenzaine, reserpine, deserpidine, and meproamate; benzodiazepines such as diazepam and chlordiazepoxide; anticonvulsants such as primidone, phenytoin, and ethosuximide; muscle relaxants and antiparkinson agents such as mephenesin, methocarbomal, cyclobenzaprine hydrochloride, trihexylphenidyl hydrochloride, levodopa/carbidopa, and

biperiden; antihypertensives such as α -methyldopa and the pivaloyloxyethyl ester of α -methyldopa; calcium channel blockers such as nifedipine, felodipine, diltiazem hydrochloride, diltiazem malate and verapamil hydrochloride; analgesics such as morphine sulfate, codeine sulfate, meperidine, and nalorphine; antipyretics and antiinflammatory agents such as aspirin, indomethacin, ibuprofen, sodium indomethacin trihydrate, salicylamide, naproxen, colchicine, fenoprofen, sulindac, diflunisal, diclofenac, indoprofen and sodium salicylamide; local anesthetics such as procaine, lidocaine, tetracaine and dibucaine; antispasmodics and muscle contractants such as atropine, scopolamine, methscopolamine, oxyphenonium, papaverine; prostaglandins such as PGE₁, PGE₂, PGF_{2 α} ; antimicrobials and antiparasitic agents such as penicillin, tetracycline, oxytetracycline, chlorotetracycline, chloramphenicol, thiabendazole, ivermectin, and sulfonamides; antimalarials such as 4-aminoquinolines, 8-amino-quinolines and pyrimethamine; hormonal and steroidal agents such as dexamethasone, prednisolone, cortisone, cortisol and triamcinolone; androgenic steroids such as methyltestosterone; estrogenic steroids such as 17 α -estradiol, α -estradiol, estriol, α -estradiol 3-benzoate,

and 17-ethynyl estradiol-3-methyl ether; progestational
steroids such as progesterone; sympathomimetic drugs such as
epinephrine, phenylpropanolamine hydrochloride, amphetamine,
ephedrine and norepinephrine; hypotensive drugs such as
5 hydralazine; cardiovascular drugs such as procainamide
hydrochloride, amyl nitrite, nitroglycerin, dipyridamole,
sodium nitrate and mannitol nitrate; diuretics such as
chlorothiazide, acetazolamide, methazolamide,
10 hydrochlorothiazide, amiloride hydrochloride and
flumethiazide, sodium ethacrynate, and furosemide;
antiparasitics such as bephenium, hydroxynaphthoate,
dichlorophen and dapsone; antineoplastics such as
15 mechlorethamine, uracil mustard, 5-fluorouracil,
6-thioguanine and procarbazine; β -blockers such as pindolol,
propranolol, metoprolol, oxprenolol, timolol maleate,
atenolol; hypoglycemic drugs such as insulin, isophane
20 insulin, protamine zinc insulin suspension, globin zinc
insulin, extended insulin zinc suspension, tolbutamide,
acetoexamide, tolazamide and chlorpropamide; antiulcer
drugs such as cimetidine, ranitidine, famotidine and
25 omeprazole; nutritional agents such as ascorbic acid,
niacin, nicotinamide, folic acid, choline, biotin,
pantothenic acid; essential amino acids; essential fats;

ophthalmic drugs such as timolol maleate, pilocarpine
nitrate, pilocarpine hydrochloride, atropine sulfate,
scopolamine; electrolytes such as calcium gluconate, calcium
lactate, potassium chloride, potassium sulfate, sodium
fluoride, ferrous lactate, ferrous gluconate, ferrous
5 sulfate, ferrous fumarate and sodium lactate; and drugs that
act on α -adrenergic receptors such as clonidine
hydrochloride; analgesic drugs such as acetaminophen,
oxycodone, hydrocodone, and propoxyphene;
10 antihypercholesterolemic drugs such as simvastatin,
pravastatin, lovastatin and gemfibrozil; antiinfective drugs
such as cefoxitin, cefazolin, cefotaxime, ciprofloxacin,
15 cephalixin, norfloxacin, amprolium, ampicillin, amoxicillin,
cefaclor, erythromycin, nitrofurantoin, minocycline,
doxycycline, cefadroxil, miconazole, clotrimazole,
phenazopyridine, clorsulon, fludalanine, pentizidone,
20 cilastin, phosphonomycin, imipenem; gastrointestinal drugs
such as bethanechol, clidinium, dicyclomine, meclizine,
prochlorperizine, trimethobenzamide, loperamide,
diphenoxylate, and metoclopramide; anticoagulant drugs such
25 as warfarin, phenindione, and anisindione; 5 α -reductase
inhibitors such as PROSCAR® and other drugs such as
trientine, cambendazole, ronidazole, rafoxinide,

dactinomycin, asparaginase, nalorphine, rifamycin,
carbamezapine, metaraminol bitartrate, allopurinol,
probenecid, diethylpropion, dihydrogenated ergot alkaloids,
nystatin, pentazocine, phenylpropanolamine, phenylephrine,
5 pseudoephedrine, trimethoprim, and ivermectin.

The above list of drugs is not meant to be
exhaustive. Many other drugs will certainly work in the
instant invention.

10 By "therapeutically effective amount" is meant that the
quantity of beneficial agent, contained in the core, which
can be delivered to the environment of use, has been
demonstrated to be sufficient to induce the desired effect
15 during studies utilizing the beneficial agent.

Other excipients such as lactose, magnesium stearate,
microcrystalline cellulose, starch, stearic acid, calcium
20 phosphate, glycerol monostearate, sucrose,
polyvinylpyrrolidone, gelatin, methylcellulose, sodium
carboxymethylcellulose, sorbitol, mannitol, polyethylene
glycol and other ingredients commonly utilized as
25 stabilizing agents or to aid in the production of tablets
may also be present in the core.

The drug can be in the core as a dispersion,
particle, granule, or powder. Also, the drug can be mixed
30

with a binder, dispersant, emulsifier or wetting agent and dyes.

The active agent may comprise from about 0.01% to about 75% of the core weight. Generally, the device can house from about 0.05 ng to about 50 grams of active agent or more, with individual devices containing, for example, about 25 ng, about 1 mg, about 5 mg, about 250 mg, about 500 mg, about 1.5 g, about 5 g, or the like.

The "polymer which upon hydration forms gelatinous microscopic particles" useful in the novel device of this invention broadly encompasses any polymer that upon hydration, is capable of producing discrete gelatinous microscopic particles which support a dispersion, including the beneficial agent, as it forms. The gelatinous forming polymer used also must move from the core surface in such a way that the beneficial agent is carried into the environment of use. Upon hydration, the gelatinous microscopic particles must be predisposed to leave the surface taking the drug with it. This assures a constant surface area exposed to the solvent of the environment of use and maintains the appropriate rate of release.

Polymers that form usable gelatinous microscopic particles, include the superabsorbant polymers such as

AQUAKEEP® J550, AQUAKEEP® J400, CARBOPOL® 974P and CARBOPOL® 934P and their pharmaceutically acceptable salts. By "pharmaceutically acceptable salts" of the polymers is meant the acid form of the polymer neutralized by converting all or a portion of the free acid functional groups to their salt form. The core of the device contains from about 5% to about 75% by weight of the dry gelatinous microscopic particle polymer.

The "polymer hydration modulator" useful in the novel device of this invention broadly encompasses any water soluble compound that can inhibit or enhance the rate of hydration of the gelatinous forming polymer of the core. Among the groups of compounds that can exert this effect are acids, bases, and the salts of acids and bases such as adipic acid, citric acid, fumaric acid, tartaric acid, succinic acid, sodium carbonate, sodium bicarbonate, betaine hydrochloride, sodium citrate, arginine, meglamine, sodium acetate, sodium phosphates, potassium phosphates, calcium phosphate, ammonium phosphate, magnesium oxide, magnesium hydroxide, sodium tartrate and tromethamine. Other compounds that can be used as polymer hydration modifiers include sugars such as lactose, sucrose, mannitol, sorbitol, pentaerythritol, glucose and dextrose. Polymers such as

microcrystalline cellulose and polyethylene glycol as well as surfactants and other organic and inorganic salts can also be used to modulate polymer hydration.

5 The hydration modulating agents are solubilized by the aqueous media of the environment and establish an environment such that the pH, ionic strength or hydrophilic character is appropriate for the desired polymer gelatinous microscopic particle hydration rate. For example, these
10 hydration modulating agents can enhance or retard the neutralization of acidic functional groups on the polymer which affects the rate of hydration.

The core compartment containing the drug, hydration
15 modulator, and gelatinous microscopic particle polymer as described herein, is typically in the form of a solid conventional tablet. Generally, the core is compressed into its final shape using a standard tablet compressing machine.
20 The core may contain compressing aids and diluents such as lactose that assist in the production of compressed tablets. The core can be comprised of a mixture of agents combined to give the desired manufacturing and delivery characteristics.
25 The number of agents that may be combined to make the core is substantially without an upper limit with the lower limit equalling two components: the gelatinous forming polymer and

the beneficial agent.

The preferred specifications for the core are summarized below and include:

1. Core Drug Loading (size): about 0.01% to about
5 75% by weight of the total core mass or about 0.05 nanogram
to about 50 grams or more (includes dosage forms for humans
and animals).
2. Polymer Hydration Modulator: 0% to about 75% by
10 weight of the total core mass.
3. Gel Forming Polymer: about 5% to about 75% by
weight of the total core mass.

15 In cases where the drug, the gelatinous forming
polymer and polymer hydration modulating agent exhibit the
desired release rate, stability, and manufacturing
characteristics, there is no critical upper or lower limit
as to the amount of drug that can be incorporated into a
20 core mass. The ratio of drug to excipient is dictated by
the desired time span and profile of release, and the
pharmacological activity of the drug.

25 Generally the core will contain 1% to 50% by weight, of
a beneficial agent admixed with other solute(s).

Representative of compositions of matter that can be
released from the device and can function as a solute are,

without limitation, those compositions as described.

The coating, applied to the core of the invention, is a material that is impermeable and insoluble in the fluid of the environment of use, can form films, and does not adversely affect the drug, animal body, or host. The
5 coating is impermeable to water and also impermeable to the selected product, drugs, polymer hydration modulating agents, or to other compounds in the device. This
10 impermeable material is insoluble in body fluids and non-erodible or it can be bioerodible after a predetermined period with bioerosion following the end of the active drug release period. In each instance it is impermeable to
15 solvent and solute(s) and is suitable for construction of the device.

By "impermeable" is meant that the influx of water across the coating is de minimus. Flux of water into the
20 device is via the apertures placed in the coating.

The polymeric coating is applied to and adheres to the entire surface of the core. Apertures are produced in the coating to expose the core, using either a drill, a coring
25 device or any other pharmaceutically accepted means.

The apertures allow liquids from the environment of use to make contact only with exposed portions of the core

when in use. The number, size and configuration of the apertures is chosen to provide the release rate required to suit a pharmacologically recognized requirement since the gelatinous dispersion can form only where the apertures allow such core-liquid contact.

5 The coating can be applied by dipping the cores into a solution of the polymer or by coating the cores using a pharmaceutically acceptable polymer coating process. Among
10 the groups of polymers that can provide this type of protection are cellulose acetate, cellulose acetate butyrate, ethylcellulose, polyvinylacetate, polyvinyl chloride and polymers of acrylic and methacrylic acid
15 esters. In addition, other materials may be included with the coating to enhance its stability, color, elasticity, ease of application or opacity. These include plasticizers such as dibutylsebacate, diethylphthalate, triethylcitrate
20 and polyethylene glycol.

The coating is applied to a thickness of from about 1 to about 1000 microns but preferably about 10 to about 500
25 microns typically, although thinner and thicker coatings fall within the scope of the invention.

The expression "aperture" as used herein, refers to ports through the coating which expose the surface of the

core to the environment. The size and number of apertures is chosen to effect the desired release rate. Exposure of from about 1% to about 75% of the core surface is contemplated by this invention.

- 5 The apertures are generally positioned in a regular pattern on both faces of the device although they can be positioned anywhere on the core including the edges or all on one face.

The apertures are generally circular but may be of any
10 design that results in the proper release rate. When the aperture is circular, its diameter ranges from about 0.1 mm to about 20 mm with diameters of about 0.2 to about 3.5 mm typical. The number of apertures in each device may range
15 from about 2 to about 1000 or more. Typically, the number of apertures in each dosage form ranges from about 5 to about 100.

20 The apertures may be made by drilling the appropriate size hole through the coating using a mechanical or laser-based process. In the preferred embodiment, a digital laser marking system is used to drill the holes required. This
25 system allows for an array of apertures to be drilled on both faces of a dosage form simultaneously and at rates suitable for production of dosage forms.

The process utilizes a digital laser marking system
30

(for example the DigiMark® variable marking system, available from Directed Energy, Inc.) to produce an unlimited number of holes through the surface or coating of the dosage form, at rates practically suitable for production of dosage forms.

5 The steps involved in this laser drilling process are as follows: a digital laser marking system is focused at a laser stage; the dosage form is moved onto the laser stage
10 of the digital laser marking system; the digital laser marking system is pulsed to energize those laser tubes needed to drill the desired apertures along a linear array on the dosage form; the dosage form is moved forward on the
15 laser stage and the digital laser marking system is again pulsed as needed to produce an additional linear array of apertures; The dosage form is then removed from the laser stage.

20 Additional, preferred specifications for the impermeable wall include: a mixture of eight parts by weight of cellulose acetate butyrate, two parts by weight of cellulose acetate and one part by weight of diethylphthalate. This
25 mixture is dissolved in a solution of methylene chloride and methanol (about 3:1 v/v) and sprayed onto the cores to a thickness of about 250 microns. Another preferred coating

30

consists of five parts by weight of cellulose acetate butyrate and one part by weight of triethyl citrate dissolved in a mixture of acetone and methanol (about 3:1 v/v). This mixture is sprayed on the core or dipped into the mixture so that a coating thickness of about 100 microns is applied.

The polymers used in the coating which are herein described are known to the art or can be prepared according to the procedures in Encyclopedia of Polymer Science and Technology, Vol. 3, published by Interscience Publishers, Inc., New York, in Handbook of Common Polymers by Scott, J. R. and Roff, W. J., 1971, published by CRC Press, Cleveland, Ohio.

The following examples illustrate the preparation of the drug delivery device of this invention and their controlled release of one or more therapeutically active ingredients into an environment of use and as such are not to be considered as limiting the invention set forth in the claims appended hereto.

EXAMPLES

In the following examples the hydroxymethyl-glutaryl-coenzyme A reductase inhibitors (HMG CoA reductase

inhibitors) simvastatin and lovastatin are used as model drugs. These drugs are highly effective in the reduction of serum cholesterol levels in humans. The aqueous solubilities of simvastatin and lovastatin are 0.03 mg/ml and 0.00044 mg/ml respectively, at 20°C. The generation of a dispersion, in situ, from the components of a solid core is disclosed. The anti-arthritic, indomethacin and the analgesic, acetaminophen serve as examples of beneficial agents which are deliverable with this device. This permits the successful formulation of poorly aqueous soluble (simvastatin, lovastatin, indomethacin), moderately soluble (acetaminophen) and freely water soluble drugs into a delivery device.

EXAMPLE 1

Tablets for the controlled release of the drug indomethacin were made as follows, utilizing a 1:1 weight ratio of drug:J-550 polymer.

Core Component	Weight (g)
AQUAKEEP® J-550	2
Indomethacin	2
Avicel PH 101	400 mg
Povidone (K29-32)	60 mg in 6 ml EtOH

Indomethacin, J-550 and Avicel were mixed thoroughly and

granulated with the polyvinylpyrrolidone as a 1% by weight solution in ethyl alcohol. The solvated mass was passed through a sieve of standard mesh size 18 then dried overnight at 45°C. Tablet cores were prepared from the resulting granulation by taking approximately 115 mg of the granules and compressing them on a Carver® press using 1/4" standard concave punches.

The tablet cores prepared as above were coated with polyvinyl chloride (PVC) coating by dip coating 5 times in diluted clear polyvinyl chloride cement. These tablets were rolled on edge each time on a teflon sheet to prevent sticking. Each tablet was allowed to dry approximately one hour between subsequent coatings and the tablets were dried for approximately 8 hours after the fifth coat was applied. Five 1.5 mm diameter circular openings were drilled through the coating on each face of the tablets.

The release of indomethacin from the coated, drilled tablets into 900 ml of pH 7.5 phosphate buffer at 37°C with 100 rpm stirring was then determined (USP Apparatus 2). The absorbance of indomethacin was measured at 320 nm using a Cary-14 spectrophotometer. Indomethacin release profiles for the coated, drilled dosage forms are shown in Fig. 2.

EXAMPLE 2

Tablets were prepared according to the procedure of Example 1 except that the core mixture comprised indomethacin and J-550 polymer in the weight ratio of 1:3. Indomethacin release rates were determined as in Example 1 and are shown in Fig. 2.

5

EXAMPLES 3 AND 4

Tablets were prepared according to the procedures of Examples 1 and 2. Core compositions of indomethacin and J-550 in a weight ratio of 1:1 and 1:3 were spray coated with cellulose acetate butyrate CAB 381-20 (Eastman Fine Chemicals) in a Freund® Model HCT-Mini Hi-Coater (8-inch pan) from a methylene chloride:methanol (1:1) solution at 4% by weight solids. Coating thicknesses were 250 microns for the 1:1 indomethacin:J-550 core composition and 400 microns for the 1:3 core composition. The indomethacin release rates were determined as in Example 1 and are shown in Fig. 2.

10

15

20

EXAMPLE 5

Tablets for the controlled release of simvastatin were prepared from the following formulation:

25

<u>Ingredient</u>	<u>mg/Tab</u>
-------------------	---------------

30

	Simvastatin	100
	AQUAKEEP® J-550	100
	Avicel PH101	100
	Povidone (K29-32)	7.8
5	Magnesium Stearate	<u>1.5</u>
	Total	<u>309.3</u>

The dry ingredients with the exception of magnesium stearate were thoroughly mixed and granulated with absolute alcohol.

10 The solvated mass was passed through a No. 18 stainless steel sieve and then dried for twenty-four hours at 37°C.

The dried granules were forced through a No. 35 mesh

15 stainless steel sieve before lubricating with magnesium stearate. This homogeneous mixture was compressed into tablets using .3/8 inch standard concave round punches. The tablets were compressed to a hardness of 19 kg. The tablets

20 were coated in a Freund® Model HCT-Mini Hi-Coater (8-inch pan) to a thickness of 250 microns using the following coating formulation:

25

30

<u>Ingredient</u>	<u>Amount</u>
-------------------	---------------

	Cellulose Acetate Butyrate CAB 381-20	48 g
	Cellulose Acetate CA 435-75S	12 g
	Methylene Chloride	2250 ml
	Methanol	750 ml
5	<u>Diethylphthalate</u>	<u>6 g</u>

Circular openings in the coating were made using a tubular boring tool with an i.d. of 2.80 mm which provided openings of nearly 3.0 mm. The in vitro release of simvastatin from
10 tablets with three circular openings of 3.0 mm diameter on each face was carried out at 37°C using USP Apparatus 2 into pH 7.4 phosphate buffer with 0.5% by weight sodium dodecyl sulfate at 100 rpm. The results are shown in Fig. 3.

15

EXAMPLE 6

Tablets for the controlled release of lovastatin were prepared from the following formulation:

20	<u>Ingredient</u>	<u>mg/Tablet</u>
	Lovastatin	20
	CARBOPOL® 974P	13.4
	Sodium Citrate Dihydrate	13.3
	Lactose Hydrous (spray dried)	13.3
25	Povidone (K29-32)	<u>3.0</u>
		63.0
	<u>Total</u>	

The ingredients were combined and thoroughly mixed in a
30 mortar and pestle, then granulated with 90% alcohol: 10% by

volume water. This wet mass was passed through a No. 20 stainless steel sieve and dried overnight at 40°C. The resulting mixture was compressed into tablets using 1/4 inch standard concave punches. The tablets were compressed to a thickness of 2.33 mm and a hardness of 9 kg.

The tablets were coated to a thickness of 250 microns with the following formulation using a Freund® Model HCT-Mini H-Coater (8-inch pan).

10	Ingredient	Amount
	Cellulose Acetate Butyrate CAB 381-20	64 g
	Cellulose Acetate CA 435-75S	16 g
	Methylene Chloride	3000 ml
15	Methanol	1000 ml
	Diethylphthalate	8 g

In vitro release tests were carried out at 37°C using USP Apparatus 2 into pH 7.4 phosphate buffer containing 0.2% sodium dodecyl sulfate at 50 rpm. The drug released was monitored by flow-through UV spectrophotometry. The drug released from coated tablets with 1.75 mm diameter circular openings bored through the coating on each face is shown in Fig. 4.

EXAMPLE 7

Simvastatin tablets were prepared from the following formulation:

Ingredients	mg/Tablet
Simvastatin	40
CARBOPOL® 974P	26.7
Sodium Citrate Dihydrate (milled to 100-200 mesh)	26.7
5 Lactose Hydrous NF (spray dried)	26.6
Povidone USP (K29-32)	6.0
Butylated Hydroxyanisole (BHA) NF	0.04
Magnesium Stearate NF	0.6
Total	126.64

10

The simvastatin, CARBOPOL®, milled sodium citrate, lactose and polyvinyl-pyrrolidone were combined, mixed thoroughly and granulated with 10% by weight water in alcohol containing the required BHA. The wet mass was forced through a No. 18 sieve and dried overnight. The dry granulation was lubricated with magnesium stearate and the homogeneous mixture compressed using 1/4 inch standard concave round tooling and a compression force of 1000 lbs. The compressed tablets had a thickness of 3.89 mm and a hardness of 10 kg. The tablets were spray coated to a coat thickness of 100 microns in a Freund® HCT-Mini Hi-Coater (8-inch pan) using the following coating formulation:

15

20

25

30

Ingredient	Amount
------------	--------

Cellulose Acetate Butyrate CAB 381-20	80 g
Triethyl Citrate	16 g
Acetone	3000 ml
Methanol	1000 ml

5 In vitro release tests were carried out at 37°C using USP
Apparatus 2 into pH 7.4 phosphate buffer containing 0.4% by
weight sodium dodecyl sulfate at 50 rpm. The drug released
was monitored by flow-through UV spectrophotometry. The
10 results for tablets with one 2.8 mm diameter circular
opening per tablet face are shown in Fig. 5

EXAMPLE 8

Tablets for the controlled release of lovastatin were
15 prepared from the following formulation:

Ingredient	mg/Tablet
Lovastatin	40
CARBOPOL® 974P NF	16
20 Sodium Citrate USP (dihydrate)	32
Lactose Hydrous NF (spray dried)	16
Povidone USP (K29-32)	5.2
Butylated Hydroxyanisole NF	0.04
Magnesium Stearate NF	<u>0.55</u>
25	109.79
Total	

The granular sodium citrate dihydrate was reduced in
particle size such that 90% by weight passed through a No.

120 mesh sieve. The milled sodium citrate dihydrate was combined with lovastatin, CARBOPOL®, lactose and polyvinylpyrrolidone, mixed thoroughly then granulated using Alcohol USP. The solvated mass was passed through a #10 screen then dried overnight at 50°C. The dried granulation was milled, then lubricated with magnesium stearate. The homogeneous mixture was compressed into tablets using 1/4 inch standard concave tooling. The tablets were compressed to a thickness of 3.43 mm and a hardness of 10.5 kg. The tablets were coated to a thickness of 100 microns with the following coating formulation using a Glatt WSG-3 fluidized bed column spray coater.

Ingredients	Amount
Cellulose Acetate Butyrate CAB 381-20	80 g
Triethyl Citrate NF	16 g
Acetone NF	3000 ml
Alcohol USP	1000 ml

In vitro release tests were carried out as in Example 7 for tablets with bored circular openings of 1.5 mm diameter and three per tablet face. The results are shown in Fig. 6.

EXAMPLE 9

Tablets for the controlled release of acetaminophen were prepared according to the following formulation:

Ingredient	mg/Tablet
Acetaminophen	20
5	CARBOPOL® 974P
Sodium Citrate Dihydrate	10
Lactose Hydrous (spray dried)	20
Povidone (K29-32)	10
Total	<u>3</u>
10	63

The ingredients above were combined, mixed thoroughly then granulated with alcohol. The solvated mass was passed through a No. 20 mesh sieve and dried overnight at 40°C.

15 The dried granulation was compressed into tablets using 1/4 inch standard concave tooling. The tablets were compressed to a thickness of 2.31 mm and a hardness of 6-7 kg. The tablets were coated as in Example 6.

20 In vitro release tests were carried out at 37°C using USP Apparatus 2 into pH 7.4 phosphate buffer at 50 rpm. The drug released was monitored by flow-through UV
25 spectrophotometry. The results for tablets with one 2.75 mm diameter circular opening per tablet are shown in Fig. 7.

EXAMPLE 10

Tablets cores containing lovastatin, CARBOPOL
974P, trisodium citrate and lactose in ratios of
5 5:2:4:2 were prepared using the procedure described in
Example 8.

Varying numbers of apertures were drilled in each
face of the coated tablets using a DIGIMARK (TM)
10 digital laser marking system. Each aperture was about
0.23 mm in diameter as measured by microscopic imaging
using an Analytical Imaging Concepts IM4000. In vitro
release tests were carried out at 37°C using USP
15 Apparatus II in pH 7.4 phosphate buffer containing 0.2%
sodium dodecyl sulfate at 50 rpm. The drug released
was monitored by flow-through UV spectrophotometry.

20 The results of the study are shown in Table I.

EXAMPLE 11

Twenty-four (24) apertures of 0.35 mm in diameter
were drilled in each face of the coated tablets
25 prepared for the study in Example 10 using the DIGIMARK
(TM) digital laser marking system. The apertures were
measured by microscopic imaging using an Analytical
Imaging Concepts IM4000. Release rates were studied as
30 in Example 1. The results are shown in Table II.

39

TABLE I.

	Number of holes	Initial Release Rate (mg/h)	Hole Diameter	Hole Surface Area	Release Rate/Hole Surface (mm/h)/mm ²
5	5	0.4	0.23	0.42	1.06
	10	0.91	0.23	0.83	1.10
	20	2.14	0.23	1.66	1.29
	40	3.57	0.23	3.32	1.07
10	1	0.35	0.53	0.44	0.79
	3	1.03	0.53	1.32	0.78
	5	1.92	0.53	2.21	0.87
	10	3.36	0.53	4.41	0.76
	5	4.28	1.07	8.99	0.48
	7	5.80	1.07	12.59	0.46
	1	1.96	1.6	4.02	0.49
	2	3.55	1.6	8.04	0.44
15	3	5.07	1.6	12.06	0.42
	1	2.22	2.0	6.28	0.35
	1	2.73	2.4	9.05	0.30
	1	4.17	3.0	14.14	0.29

20

TABLE II

	Number of holes	Initial Release Rate (mg/h)	Hole Surface Area (mm ²)	Release Rate/Hole Surface Area (mg/h)mm ²
25	24	3.96	4.62	0.86

30

What is claimed is:

1. A drug delivery device for the controlled in situ production and release of a dispersion containing a beneficial agent, consisting essentially of:

5 (A) a compressed core prepared from an admixture comprising

(i) from 0.01% to 75% by weight of a therapeutically effective amount of a beneficial agent; and

10 (ii) from 5% to 75% by weight of a water insoluble, water impermeable polymeric coating, which surrounds and adheres to the core, the coating having apertures, exposing about 1 and about 75% of the core surface;

wherein, the polymer which upon hydration forms gelatinous microscopic particles is selected from the group consisting of sodium polyacrylate, and carboxypolymethylenes prepared from acrylic acid cross-linked with allylethers of sucrose or pentaerythritol and the pharmaceutically acceptable salts thereof.

2. The device of Claim 1, wherein the beneficial agent is an HMG CoA reductase inhibitor such as lovastatin, pravastatin and simvastatin.

30

3. The device of Claim 1 wherein the beneficial agent is an anti-inflammatory such as indomethacin.
4. The device of Claim 1, wherein the core mixture further comprises a polymer hydration modulating agent selected from the group consisting of acids,
5 bases, salts, sugars, surfactants and soluble polymers.
5. The device of claim 1 wherein the insoluble,
10 impermeable coating is comprised of a polymeric material such as polyvinyl chloride, cellulose acetate, cellulose acetate butyrate or ethylcellulose.
- 15 6. The device of Claim 1 wherein the number of apertures ranges from 2 to about 100 and the apertures range from 0.1 mm to 20 mm at their widest point.
- 20 7. A drug delivery device of Claim 1, for the controlled in situ production and release of a dispersion containing lovastatin, consisting essentially of:
25 (A) a compressed core prepared from an admixture comprising
(i) a therapeutically effective amount of
30 lovastatin;

(ii) a polymer which forms gelatinous microscopic particles upon hydration; and

(iii) an effective amount of sodium citrate as a polymer hydration modulating agent;

5 (B) an insoluble, impermeable polymeric coating comprising cellulose acetate butyrate which surrounds and adheres to the core and containing apertures which expose between 1% and 75% of the core surface.

8. The drug delivery device of Claim 7, wherein the polymer is a carboxypolymethylene prepared from acrylic acid cross-linked with allylethers of
15 sucrose or pentaerythritol.

9. The drug delivery device of Claim 8, wherein the insoluble, impermeable polymeric coating contains from about three to about 100 apertures.

20 10. A process for the preparation of the device of Claim 1 for the controlled release of an active agent wherein:

25 (A) the core is prepared by either dry mixing or wet granulating the polymer which upon hydration produces gelatinous microscopic particles, the medicament and other excipients
30 required in the preparation of tablets and

43

compressing the mixture into cores;

(B) coating the entire core with the coating material;

and

5 (C) drilling apertures through the coating using a laser or mechanical drilling device.

10

15

20

25

30

1/7




FIG. 1

2/7




FIG. 2

3/7




FIG. 3

4/7




FIG. 4

5/7




FIG. 5

6/7




FIG. 6

7/7




FIG. 7

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 A61K9/00; A61K9/20											
II. FIELDS SEARCHED <div style="text-align: center; border: 1px solid black; padding: 2px;">Minimum Documentation Searched⁷</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; padding: 5px;">Classification System</th> <th style="padding: 5px;">Classification Symbols</th> </tr> <tr> <td style="padding: 5px;">Int.Cl. 5</td> <td style="padding: 5px;">A61K</td> </tr> </table> <div style="text-align: center; border: 1px solid black; padding: 2px;">Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched⁸</div>			Classification System	Classification Symbols	Int.Cl. 5	A61K					
Classification System	Classification Symbols										
Int.Cl. 5	A61K										
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%; padding: 5px;">Category¹⁰</th> <th style="padding: 5px;">Citation of Document,¹¹ with indication, where appropriate, of the relevant passages¹²</th> <th style="width: 15%; padding: 5px;">Relevant to Claim No.¹³</th> </tr> </thead> <tbody> <tr> <td style="vertical-align: top; padding: 5px;">X Y</td> <td style="padding: 5px;"> EP,A,0 378 404 (PFIZER INC.) 18 July 1990 see claims 1,2,18 see page 2, line 28 - line 40 see page 4, line 2 - line 4 see page 5, line 18 - line 30 see page 5, line 52 - line 56 see page 7, line 47 - line 54 see example 1 see figures 1-2 <div style="text-align: center;">---</div> </td> <td style="vertical-align: top; padding: 5px;"> 1,4-6, 8-10 2,3,7 </td> </tr> <tr> <td style="vertical-align: top; padding: 5px;">Y</td> <td style="padding: 5px;"> <div style="text-align: center;">---</div> US,A,4 915 954 (ATUL D. AYER ET AL.) 10 April 1990 see claim 3 see column 6, line 19 - line 65 see column 9, line 64 - column 10, line 16 <div style="text-align: center;">---</div> <div style="text-align: right; margin-top: 20px;">-/--</div> </td> <td style="vertical-align: top; padding: 5px;"> 2,7 </td> </tr> </tbody> </table>			Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³	X Y	EP,A,0 378 404 (PFIZER INC.) 18 July 1990 see claims 1,2,18 see page 2, line 28 - line 40 see page 4, line 2 - line 4 see page 5, line 18 - line 30 see page 5, line 52 - line 56 see page 7, line 47 - line 54 see example 1 see figures 1-2 <div style="text-align: center;">---</div>	1,4-6, 8-10 2,3,7	Y	<div style="text-align: center;">---</div> US,A,4 915 954 (ATUL D. AYER ET AL.) 10 April 1990 see claim 3 see column 6, line 19 - line 65 see column 9, line 64 - column 10, line 16 <div style="text-align: center;">---</div> <div style="text-align: right; margin-top: 20px;">-/--</div>	2,7
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³									
X Y	EP,A,0 378 404 (PFIZER INC.) 18 July 1990 see claims 1,2,18 see page 2, line 28 - line 40 see page 4, line 2 - line 4 see page 5, line 18 - line 30 see page 5, line 52 - line 56 see page 7, line 47 - line 54 see example 1 see figures 1-2 <div style="text-align: center;">---</div>	1,4-6, 8-10 2,3,7									
Y	<div style="text-align: center;">---</div> US,A,4 915 954 (ATUL D. AYER ET AL.) 10 April 1990 see claim 3 see column 6, line 19 - line 65 see column 9, line 64 - column 10, line 16 <div style="text-align: center;">---</div> <div style="text-align: right; margin-top: 20px;">-/--</div>	2,7									
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>¹⁰ Special categories of cited documents: ¹⁰</p> <p>¹⁰ "A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>¹⁰ "E" earlier document but published on or after the international filing date</p> <p>¹⁰ "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>¹⁰ "O" document referring to an oral disclosure, use, exhibition or other means</p> <p>¹⁰ "P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>¹⁰ "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>¹⁰ "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>¹⁰ "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>¹⁰ "Δ" document member of the same patent family</p> </div> </div>											
IV. CERTIFICATION <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; padding: 5px;"> Date of the Actual Completion of the International Search <div style="text-align: center; font-weight: bold;">31 MARCH 1993</div> </td> <td style="width: 50%; padding: 5px;"> Date of Mailing of this International Search Report <div style="text-align: center; font-weight: bold;">26. 04 93</div> </td> </tr> <tr> <td style="padding: 5px;"> International Searching Authority <div style="text-align: center; font-weight: bold;">EUROPEAN PATENT OFFICE</div> </td> <td style="padding: 5px;"> Signature of Authorized Officer <div style="text-align: center; font-weight: bold;">VENTURA AMAT A.</div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="text-align: center; font-weight: bold;">31 MARCH 1993</div>	Date of Mailing of this International Search Report <div style="text-align: center; font-weight: bold;">26. 04 93</div>	International Searching Authority <div style="text-align: center; font-weight: bold;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center; font-weight: bold;">VENTURA AMAT A.</div>					
Date of the Actual Completion of the International Search <div style="text-align: center; font-weight: bold;">31 MARCH 1993</div>	Date of Mailing of this International Search Report <div style="text-align: center; font-weight: bold;">26. 04 93</div>										
International Searching Authority <div style="text-align: center; font-weight: bold;">EUROPEAN PATENT OFFICE</div>	Signature of Authorized Officer <div style="text-align: center; font-weight: bold;">VENTURA AMAT A.</div>										

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
Y	FR,A,2 620 025 (ALZA CORPORATION) 10 March 1989 see claims 1,4 see page 11, line 9 - line 36 see page 15, line 33 - page 16, line 9 -----	3

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

US 9211014
SA 68618

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 31/03/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0378404	18-07-90	AU-B- 615129	19-09-91
		AU-A- 4787790	19-07-90
		CA-A- 2007463	12-07-90
		JP-A- 2229110	11-09-90

US-A-4915954	10-04-90	US-A- 4814181	21-03-89
		AU-A- 2152688	09-03-89
		BE-A- 1001184	08-08-89
		CH-A- 676794	15-03-91
		DE-A- 3829942	16-03-89
		FR-A- 2620025	10-03-89
		GB-A, B 2209280	10-05-89
		JP-A- 1096116	14-04-89
		LU-A- 87326	08-03-89
		NL-A- 8802180	03-04-89
		SE-A- 8803084	04-03-89
		US-A- 4915953	10-04-90

FR-A-2620025	10-03-89	US-A- 4814181	21-03-89
		AU-A- 2152688	09-03-89
		BE-A- 1001184	08-08-89
		CH-A- 676794	15-03-91
		DE-A- 3829942	16-03-89
		GB-A, B 2209280	10-05-89
		JP-A- 1096116	14-04-89
		LU-A- 87326	08-03-89
		NL-A- 8802180	03-04-89
		SE-A- 8803084	04-03-89
		US-A- 4915953	10-04-90
		US-A- 4915954	10-04-90

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.